Pharming Group Might Have An Effective COVID-19 Treatment Ready For Use [Seeking Alpha]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Seeking Alpha
SummaryPharming Group has commercialized only one FDA-approved product, Ruconest. It is a recombinant therapy for people suffering from hereditary angioedema.Ruconest may also be an effective treatment for critically ill COVID-19 patients. In particular, Ruconest might be able to stop or dampen the severe cytokine storm seen in some patients.The likelihood of Ruconest being effective for critical COVID-19 patients is bigger than the market deems.Pharming Group is profitable, and selling at a modest valuation, showcasing a low downside and a relatively high upside.Pharming Group is currently 20% below its 2020 high, despite the major earnings potential ahead.In this write-up, I will discuss why Pharming Group's (OTCPK:PHGUFIntroduction to PharmingPharming group is a specialitypharmaceutical companyRuconest is Pharming's gem. It is a recombinant therapy for people suffering from hereditary angioedema, HAE for short. Originally, it was meant as a preventive therapy. However, it is now us
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- Gilead (GILD) Valuation After Fresh Buy Rating and Extended Biktarvy Exclusivity Boost Investor Confidence [Yahoo! Finance]Yahoo! Finance
- Madonna pens scathing post against Trump for 'unthinkable' decision to ignore World AIDS Day [FOX News]FOX News
- Mableton man uses TikTok to fight HIV stigma as federal government skips World AIDS Day recognition [CBS News]CBS News
- Elton John reveals what would make Trump one of the 'greatest presidents' in history [FOX News]FOX News
- National AIDS Memorial Marks World AIDS Day with Two Signature Events Highlighting the Power of Communities to Shape Progress in the Fight Against HIV/AIDS and Advance Health and Social Justice [Yahoo! Finance]Yahoo! Finance
GILD
Earnings
- 10/30/25 - Beat
GILD
Sec Filings
- 12/1/25 - Form 4
- 12/1/25 - Form 4
- 12/1/25 - Form 4
- GILD's page on the SEC website